131 related articles for article (PubMed ID: 11564090)
21. Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor.
Kanda Y; Tanosaki R; Nakai K; Saito T; Ohnishi M; Niiya H; Chizuka A; Yakushijin K; Urahama N; Ueda K; Iijima K; Ando T; Matsubara H; Kami M; Makimoto A; Kobayashi Y; Tobinai K; Mineishi S; Takaue Y
Br J Haematol; 2002 Jul; 118(1):128-31. PubMed ID: 12100136
[TBL] [Abstract][Full Text] [Related]
22. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
Mattsson J; Uzunel M; Remberger M; Hassan M
Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
[TBL] [Abstract][Full Text] [Related]
23. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
[TBL] [Abstract][Full Text] [Related]
24. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
26. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation.
Wäsch R; Bertz H; Kunzmann R; Finke J
Br J Haematol; 2000 Jun; 109(4):743-50. PubMed ID: 10929024
[TBL] [Abstract][Full Text] [Related]
27. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Frassoni F; Sessarego M; Fugazza G; Di Stefano F; Pitto A; Bacigalupo A
Br J Haematol; 2000 Jun; 109(4):716-21. PubMed ID: 10929020
[TBL] [Abstract][Full Text] [Related]
28. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
29. Liposomal busulphan: bioavailability and effect on bone marrow in mice.
Hassan Z; Nilsson C; Hassan M
Bone Marrow Transplant; 1998 Nov; 22(9):913-8. PubMed ID: 9827821
[TBL] [Abstract][Full Text] [Related]
30. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.
Nath CE; Earl JW; Pati N; Stephen K; Shaw PJ
Br J Clin Pharmacol; 2008 Jul; 66(1):50-9. PubMed ID: 18341668
[TBL] [Abstract][Full Text] [Related]
31. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
[TBL] [Abstract][Full Text] [Related]
32. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation.
Bostrom B; Enockson K; Johnson A; Bruns A; Blazar B
Pediatr Transplant; 2003; 7 Suppl 3():12-8. PubMed ID: 12603688
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma.
Shaughnessy P; Alexander W; Tran H; Ririe D; Splichal J; Pollack M; Bachier C; LeMaistre C
Mil Med; 2006 Feb; 171(2):161-5. PubMed ID: 16578989
[TBL] [Abstract][Full Text] [Related]
34. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
[TBL] [Abstract][Full Text] [Related]
35. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
Ferrara F; Mele G; Palmieri S; Pedata M; Copia C; Riccardi C; Izzo T; Criscuolo C; Musto P
Hematol Oncol; 2009 Dec; 27(4):198-202. PubMed ID: 19475701
[TBL] [Abstract][Full Text] [Related]
36. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
37. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
[TBL] [Abstract][Full Text] [Related]
38. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
Cappelli B; Chiesa R; Evangelio C; Biffi A; Roccia T; Frugnoli I; Biral E; Noè A; Fossati M; Finizio V; Miniero R; Napolitano S; Ferrua F; Soliman C; Ciceri F; Roncarolo MG; Marktel S
Br J Haematol; 2009 Nov; 147(4):554-60. PubMed ID: 19747363
[TBL] [Abstract][Full Text] [Related]
39. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]